Investors Urged to Respond to Altimmune Securities Fraud Investigation by Pomerantz Law Firm

Investor Alert: Pomerantz Law Firm Probes into Altimmune, Inc. Claims

Pomerantz LLP, a renowned law firm specializing in corporate and securities class action litigation, has initiated an inquiry into potential claims on behalf of investors in Altimmune, Inc. (NASDAQ: ALT). This investigation stems from concerns that Altimmune's officers and directors may have engaged in securities fraud or other unlawful business practices. Investors are encouraged to reach out to Danielle Peyton for inquiries regarding the situation.

On June 26, 2025, Altimmune disseminated press releases detailing the findings from the IMPACT Phase 2b clinical trial of pemvidutide, intended for use in treating metabolic dysfunction-associated steatohepatitis (MASH). While the company presented the trial results as “positive,” it was notable for revealing that the fibrotic improvement observed in the treated groups did not achieve statistical significance when compared to placebo, which set alarm bells ringing among investors.

The release highlighted that the improvement in fibrosis for patients on the pemvidutide was recorded at 31.8% and 34.5% for the dosages of 1.2 mg and 1.8 mg, respectively, as opposed to 25.9% for the placebo group. The lack of statistical significance in these results led to a drastic decrease in Altimmune's stock price by $4.10 per share, representing a stunning decline of 53.18% to close at $3.61 per share on the same day.

In response to the fallout from these revelations, Pomerantz LLP has stepped in, guided by a commitment to uphold the rights of investors who may have suffered financial losses due to alleged fraudulent practices. Founded by the late Abraham L. Pomerantz, who is credited with establishing standards within the class action bar, the firm has a storied history spanning over 85 years of advocating for victims of securities fraud and corporate wrongdoing.

Potential class action members are reminded that previous outcomes in similar cases do not guarantee future results; nonetheless, Pomerantz has been instrumental in recovering millions of dollars for affected shareholders. Investors who believe they may be entitled to compensation are invited to contact the firm via the provided details to explore their legal options further.

Pomerantz operates internationally with offices based in major cities, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, thus maintaining a significant presence in worldwide class-action litigation. Their seasoned team is adept at navigating the complexities of corporate legal matters, particularly within the ever-evolving biotech sector that includes Altimmune.

In light of these events, it is pivotal for investors who suspect that they have been misled or defrauded to remain vigilant, particularly as additional information unfolds regarding Altimmune's clinical trial outcomes and any ensuing legal proceedings. Further communications from Pomerantz Law Firm and updates related to the aforementioned investigation will be crucial touchpoints for those involved.

In conclusion, investors are implored to stay proactive regarding their interests as this probe into Altimmune continues to evolve, especially in a field marked by rapid developments and volatile market responses. This case serves as a reminder of the importance of transparency in the biotech industry and the necessity of holding firms accountable for their representations to investors.